MERIT-2 : Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerabilty and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MERIT-2
- Sponsors Actelion Pharmaceuticals
- 30 Oct 2019 Planned primary completion date changed from 22 Dec 2020 to 22 Dec 2019.
- 01 Aug 2018 Trial has been completed in Czech Republic.
- 29 Jan 2018 Planned End Date changed from 28 Sep 2018 to 22 Dec 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History